Bayer’s Two-Front Legal Battle Takes Center Stage as Q2 Results Loom
Published on 07/22/2026 at 14:12 | Redaktion boerse-global.de
The weeks ahead for Bayer are shaping up to be a study in contrasts. On one side, the company has quietly defused a trade dispute that risked alienating its core agricultural customers. On the other, the US Supreme Court is weighing a decision that could fundamentally reshape the multibillion-dollar litigation overhang that has weighed on the stock for years. And somewhere in between, the group’s second-quarter earnings are due in early August, offering investors a fresh look at whether the underlying business can keep generating enough cash to absorb the legal shocks.
A Tactical Retreat on Tariffs
Bayer’s Monsanto subsidiary had filed a petition seeking anti-dumping duties of between 68.9% and 446.47% on glyphosate imports from China. The move drew sharp pushback from US farm groups, including the National Corn Growers Association, the American Soybean Association and the National Association of Wheat Growers, who warned that steep tariffs would drive up herbicide costs for their members. On July 21, Monsanto withdrew the request entirely. The subsidiary Ruveon said it would maintain its market-oriented pricing strategy, and the agricultural associations welcomed the decision as a relief for farmers already navigating tight margins.
The retreat resolves a tension that had put Bayer in an awkward spot, caught between protecting its own commercial interests and preserving relationships with the very customers who buy its crop protection products. For investors, the move removes a short-term irritant and stabilises the company’s standing in the US farm belt.
The Supreme Court Wild Card
Far more consequential is the case now before the US Supreme Court. The justices are examining whether federal law preempts state-level lawsuits against Bayer over Roundup, the glyphosate-based herbicide at the centre of tens of thousands of claims. Bayer has long argued that federal approval of the product should block state tort claims — a position that, if upheld, would sharply limit future damages.
The hearing has drawn political attention. Activists from the “MAHA moms” movement have protested outside the court, warning of electoral consequences in the upcoming midterm elections if the justices side with Bayer. US Health Secretary Robert F. Kennedy Jr. has publicly stated that glyphosate causes cancer, adding a political layer to an already charged debate. The EPA is also scheduled to review the active ingredient in October 2026, a process that could shift the regulatory landscape further.
The debate around chemical safety in the workplace highlights a wider challenge for employers: keeping risk assessments up to date with changing regulations. A free toolkit provides 41 ready-to-use templates and checklists to help you document hazards and stay compliant. Download the free Risk Assessment Toolkit
Earnings Season Brings the Numbers Into Focus
Against this legal backdrop, Bayer’s second-quarter results — due in early August for the period ending June 30, 2026 — will give investors their first hard data on how the business is performing. Analysts expect earnings per share of €0.769, but the figure requires careful interpretation. Bayer reports both a stated and an adjusted (core) profit, and the gap between them is wide.
In the same quarter a year earlier, the company reported a loss of €0.20 per share on a reported basis, while the core figure came in at €1.23 — a 30.9% year-on-year improvement. The discrepancy stems from special items tied to litigation provisions and impairments, which depress the stated result but are stripped out of the core number. The consensus estimate of €0.769 for Q2 2026 is not directly comparable to the prior-year loss for the same reason.
Revenue is expected to be essentially flat. Seven analysts forecast sales of €10.73 billion, a marginal dip from €10.74 billion a year earlier.
Full-Year Guidance and the Cash Flow Question
For the full year, Bayer’s management has guided for revenue between €45 billion and €47 billion, with core earnings per share in a range of €4.30 to €4.80. Analysts are broadly aligned, with a consensus revenue estimate of €45.68 billion and a reported EPS forecast of €4.38 — a sharp recovery from the €3.68 loss booked in 2025.
The core EPS figure for 2025 was €4.91, meaning the 2026 guidance implies a slight moderation from that level. The real pressure point, however, is cash flow. Bayer has set aside roughly €5 billion in payouts for 2026 to settle ongoing litigation, a sum that will weigh heavily on free cash generation. The company’s total provisions and liabilities from lawsuits now stand at €11.8 billion, and the €7.5 billion in special charges booked in 2025 underscores how deeply the legal legacy is embedded in the financials.
When managing hazardous substances like glyphosate, a proper COSHH risk assessment is a legal requirement for UK employers. A free toolkit offers 43 customisable templates, checklists, and toolbox talks to help you meet your compliance duties. Get the free COSHH Toolkit
Stock Holds Its Ground Despite the Noise
The shares have shown surprising resilience. After dipping to €46.70 on Wednesday — a 1.89% decline from the prior close of €47.60 — the stock remains firmly in positive territory for the year. The gain since January stands at 26.18% according to one measure, or 29.10% according to another, depending on the reference point. Either way, the trajectory is clearly upward, even if the path has been volatile: annualised volatility is running at roughly 63%.
The stock hit a 52-week high of €53.86 in early July, and the current level sits about 11% below that peak. The market appears to be pricing in cautious optimism that the Supreme Court could deliver a decisive legal win, while the withdrawal of the tariff petition removes a secondary source of friction.
For now, all eyes are on early August. The Q2 report will show whether Bayer’s operational strength in pharmaceuticals and agriculture can continue to offset the legal drag — and whether the €5 billion in planned litigation payouts fits within the company’s own guidance, or threatens to break it.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
